This newsletter presents you the following key sessions:
1. Adding tucatinib to T-DM1 significantly delays disease progression in patients with HER2+ locally
advanced/metastatic breast cancer
2. Adding pembrolizumab to neoadjuvant chemotherapy improves pCR rates across diverse subgroups in
ER+/HER2- breast cancer
3. The addition of atezolizumab to adjuvant chemotherapy in early triple-negative breast cancer is unlikely to
enhance treatment efficacy
4. Safely omitting regional nodal irradiation in patients with lymph node-negative disease after neoadjuvant
chemotherapy
5. Younger postmenopausal patients with early-stage breast cancer may safely omit adjuvant radiotherapy
following breast-conserving surgery